A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome

• Status: Unknown status
• Trial end date: 2020-07-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is to test the feasibility and tolerability of the metoprolol optimal dosing pathway by observing the percentage of patients achieving target dose followed the pathway on ACS patients during hospitalization.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yun Dai Chen
• Treatments: Metoprolol

Criteria

Inclusion Criteria:

• Aged 18 years or above;

• Hospitalized due to acute coronary syndrome;

• Able and willing to provide written informed consent and to comply with the study.

Exclusion Criteria:

• Cardiac shock;

• Unstable heart failure;

• Beta-agonist therapy on a continuous or intermittent basis;

• Hypotension (BP<90/60 mmHg) or bradycardia (HR<50 bpm) with symptoms;

• Sick sinus syndrome;

• Ⅱ~Ⅲ atrioventricular block;

• Killip >Ⅱ;

• Suspected acute myocardial infarction with heart rate<45 beats/min, P- R interval>0.24 sec or systolic blood pressure <100 mmHg;

• Existing contraindication for metoprolol or allergic to metoprolol or any excipients;

• Participation in another clinical study with an investigational product during the last 3 months;

• Previous enrolment in the present study;

• Subjects the investigator thinks not suitable for this study. E.g. cancer etc.;

• Inability to sign the informed consent form;

• Pregnancy or lactation.